Please provide your email address to receive an email when new articles are posted on . Tacrolimus alone had a dose-response relationship with achieving complete renal response in SLE. Combination ...
PHILADELPHIA, Aug. 30, 2021 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL, an internally ...
Review the side-effects of Mycophenolate Mofetil as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...
Children with frequently relapsing or steroid-dependent nephrotic syndrome had a significantly longer relapse-free survival period with tacrolimus than with mycophenolate mofetil. Relapse-free ...
Please provide your email address to receive an email when new articles are posted on . In a real-world retrospective study, researchers found mycophenolate mofetil treatment to be safe and effective ...
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), CellCept for oral suspension, 200 mg/m; of Roche Palo Alto, LLC, it added. The approval bolsters the ...
† One patient had MMF as an initial treatment. ‡ In the study TAC and MMF were used alone or in combination. §In total, 17 patients were initially treated with MMF and steroids. ¶ Females represented ...
November 12, 2010 — Azathioprine is more successful than treatment with mycophenolate mofetil in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in remission, new ...
The use of mycophenolate mofetil (MMF) for prophylaxis of aGVHD and/or for treatment of acute or chronic GVHD is increasing. However, the benefit of MMF as an alternative to commonly used ...
Substantial evidence exists that patients with scleroderma have immune dysfunction and autoimmunity, and several studies support the use of immunosuppressive treatment in these patients. Nihtyanova et ...
The addition of mycophenolate mofetil (MMF) to a glucocorticoid as a first-line treatment for immune thrombocytopenia (ITP) resulted in greater responses and a reduced risk of relapse or refractory ...
A phase 3 trial explored which treatment option for pemphigus vulgaris, a rare skin disease, resulted in better outcomes after 52 weeks. In patients with pemphigus vulgaris, rituximab was superior to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results